LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

Search

CytoSorbents Corp

Closed

SectorHealthcare

1.14 -1.72

Overview

Share price change

24h

Current

Min

1.11

Max

1.19

Key metrics

By Trading Economics

Income

6.4M

-1.5M

Sales

-423K

8.7M

EPS

-0.144

Profit margin

-16.94

Employees

149

EBITDA

8.1M

-468K

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

-16.67% downside

Dividends

By Dow Jones

Next Earnings

12 Aug 2025

Market Stats

By TradingEconomics

Market Cap

24M

79M

Previous open

2.86

Previous close

1.14

News Sentiment

By Acuity

67%

33%

336 / 380 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

CytoSorbents Corp Chart

Past performance is not a reliable indicator of future results.

Related News

25 Jun 2025, 22:09 UTC

Earnings

Alimentation Couche-Tard 4Q Profit Falls on Lower Fuel Prices, Demand

25 Jun 2025, 21:19 UTC

Acquisitions, Mergers, Takeovers

Solventum Removes Drinking-Water Unit From Thermo Fisher's Planned Filtration Buy

25 Jun 2025, 20:38 UTC

Earnings

Micron Technology 3Q Profit Soars as AI Boom Boosts Sales

25 Jun 2025, 23:49 UTC

Market Talk

Nikkei May Rise as Fears Over Middle East Ease -- Market Talk

25 Jun 2025, 23:39 UTC

Market Talk

Gold Edges Higher Amid U.S. Tariff Uncertainties -- Market Talk

25 Jun 2025, 23:13 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Xero Probably Sees Value in Melio's Syndication Network -- Market Talk

25 Jun 2025, 23:13 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Global Equities Roundup: Market Talk

25 Jun 2025, 21:36 UTC

Earnings

Jefferies' Profit Falls 40%. CEO Strikes Positive Tone on Dealmaking Outlook. -- Barrons.com

25 Jun 2025, 21:34 UTC

Earnings

Jefferies' Profit Falls 40%. CEO Strikes Positive Tone on Dealmaking Outlook. -- Barrons.com

25 Jun 2025, 21:23 UTC

Earnings

Micron's Profit Soars as AI Boom Boosts Sales -- Update

25 Jun 2025, 21:08 UTC

Earnings

Couche-Tard 4Q Canada Same-Store Merchandise Revenues Up 3.5% >ATD.T

25 Jun 2025, 21:07 UTC

Earnings

Couche-Tard 4Q U.S. Same-Store Merchandise Revenues Down 0.4% >ATD.T

25 Jun 2025, 21:05 UTC

Earnings

Couche-Tard 4Q Rev $16.27B >ATD.T

25 Jun 2025, 21:05 UTC

Earnings

Couche-Tard 4Q Adj EPS 46c >ATD.T

25 Jun 2025, 21:05 UTC

Earnings

Couche-Tard 4Q EPS 46c >ATD.T

25 Jun 2025, 21:05 UTC

Earnings

Couche-Tard 4Q Net $439.4M >ATD.T

25 Jun 2025, 20:49 UTC

Earnings

Micron Reports Strong Earnings. The Stock is Up. -- Barrons.com

25 Jun 2025, 20:32 UTC

Earnings

FedEx Earnings Topped Estimates. The Stock Is Fell. -- Barrons.com

25 Jun 2025, 20:27 UTC

Earnings

Winnebago Stock Hits a 5-Year Low. What It Means for the RV Industry. -- Barrons.com

25 Jun 2025, 20:26 UTC

Earnings

These Stocks Moved the Most Today: BP, FedEx, QuantumScape, BlackBerry, Nvidia, AeroVironment, and More -- Barrons.com

25 Jun 2025, 20:24 UTC

Earnings

Micron Reports Strong Earnings. The Stock is Up. -- Barrons.com

25 Jun 2025, 20:10 UTC

Earnings

Micron Reports Strong Earnings. The Stock is Up. -- Barrons.com

25 Jun 2025, 20:04 UTC

Earnings

Micron Technology Sees 4Q Adj EPS $2.35-Adj EPS $2.65 >MU

25 Jun 2025, 20:04 UTC

Earnings

Micron Technology Sees 4Q EPS $2.14-EPS $2.44 >MU

25 Jun 2025, 20:03 UTC

Earnings

Micron Technology Sees 4Q Rev $10.4B-$11B >MU

25 Jun 2025, 20:02 UTC

Earnings

Micron Technology: On Track to Deliver Record Rev With Solid Profitability and Free Cash Flow in FY25 >MU

25 Jun 2025, 20:02 UTC

Earnings

Micron Technology: Record Rev in Fiscal 3Q With Growth Across End Markets >MU

25 Jun 2025, 20:01 UTC

Earnings

Micron Technology 3Q Net $1.89B >MU

25 Jun 2025, 20:01 UTC

Earnings

Micron Technology 3Q Adj EPS $1.91 >MU

25 Jun 2025, 20:01 UTC

Earnings

Micron Technology 3Q EPS $1.68 >MU

Peer Comparison

Price change

CytoSorbents Corp Forecast

Price Target

By TipRanks

-16.67% downside

12 Months Forecast

Average 1 USD  -16.67%

High 1 USD

Low 1 USD

Based on 1 Wall Street analysts offering 12 month price targets forCytoSorbents Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

1 ratings

0

Buy

1

Hold

0

Sell

Technical Score

By Trading Central

0.705 / 0.771Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Very Strong Bearish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

336 / 380 Healthcare

News Sentiment

Bearish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About CytoSorbents Corp

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.